Disrupted Healthcare – 22 Deals and Investments This Week

VC Deals (19 deals, $397M)

Jibo, a Boston-based developer of “social robots” for homes, has raised an undisclosed amount of VC funding from Fenox Venture Capital. The company previously raised $34.5 million in VC funding this year from RRE Ventures, CRV, Acer, Dentsu Ventures, KDDI, LG Uplus and NetPosa

Peloton, an at-home fitness solution for live and on-demand indoor cycling classes, has raised $75 million in growth equity funding from Catterton Partners. Earlier this year the company raised $30 million in Series C funding co-led by True Ventures and Tiger Global

ORIC Pharmaceuticals, a South San Francisco-based developer of drugs that target treatment-resistant cancers, has raised $53 million in Series B funding. Backers include The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Foresite Capital and KKR

Evariant, a Farmington, Conn.-based CRM platform for healthcare providers, has raised $42.3 million in Series C funding. Goldman Sachs led the round, and was joined by return backers Health Enterprise Partners and Lightspeed Venture Partners

Kesios Therapeutics Ltd., a London-based developer of therapeutics for the treatment of multiple myeloma and other cancers, has raised £19 million ($28.5m) in Series A funding. Backers include Imperial Innovations Group PLC, SV Life Sciences and Abingworth

Remedy Pharmaceuticals, a New York-based developer of drugs to treat acute CNS disorders, has raised $9 million in VC funding. New investors included The Vertical Group

Welltok, a Denver-based health optimization platform, has acquiredSilverlink, a Burlington, Mass.-based healthcare consumer communications company. To support the deal, Welltok has raised $45 million in funding from new investors Georgian Partners, EDBI, Flare Capital and undisclosed existing investors. The company previously had raised over $100 million. Silverlink shareholders included HLM Venture Partners,Kaiser Permanente Ventures and Sigma Prime

True North Therapeutics, a South San Francisco-based developer of therapies that inhibit the complement system to treat rare diseases, has raised $40 million in Series C funding. New Leaf Venture Partners led the round, and was joined by Perceptive Advisors, Cowen Private Investments and return backers Kleiner Perkins Caufield & Byers, MPM Capital, OrbiMed, SR One and Baxalta Ventures

Velicept Therapeutics Inc., a Malvern, Penn.-based developer of a beta 3-adrenoceptor agonist for the treatment of overactive bladder, has raised $21 million in Series B funding co-led by CAM Capital and Longitude Capital

Clearside Biomedical Inc., an Alpharetta, Ga.-based developer of therapies to treat blinding diseases of the eye, has raised $20 million in Series C funding. New investors included Aju IB Investment, Cormorant Asset Management, Perceptive Advisors and Rock Springs Capital Management

Enlibrium, a San Diego-based developer of “drugs based on the anti-cancer activity of metformin,” has raised $15 million in Series A funding. Avalon Ventures and TPG Biotech co-led the round, and were joined by Correlation Ventures and Osage University Partners

Contessa Health Inc., a Nashville, Tenn.-based creator and manager of home hospitalization programs, has raised $3.5 million in Series A funding from BlueCross BlueShield Venture Partners, Sandbox Advantage Fund and Martin Ventures

GOQii, a 1.5-year-old, Menlo Park, Ca.-based wearable and fitness technology startup, has raised $13.4 million in Series A funding led by New Enterprise Associates, with participation from Cheetah Mobile; Great Wall Club; DSG Consumer Partners; and numerous individual investors

Pluss, a month-old, Gurgaon, India-based on-demand medicine and healthcare products delivery service startup, has raised $1 million in pre-Series A funding from IDG Ventures India, m & s partners in Singapore, andPowerhouse Ventures in the U.S

Vector Watch, a two-year-old Bucharest-based maker of a low-power operating system for wearables, has raised $5 million in funding led by GECAD Group, with participation from Catalyst Romania

Soliton, a new, Houston-based stealth-mode startup whose technology will aid in methods for medical and cosmetic treatments using electro-hydraulic generated shockwaves (it was developed out of the University of Texas M.D. Anderson Cancer Center), has raised $9 million, according to an SEC filing

Neurona Therapeutics, a 4.5-year-old, South San Francisco, Ca.-based biotechnology company focused on the transplantation of selected neurons to treat intractable neurological diseases, has raised $23.5 million in Series A funding led by The Column Group

Wiivv Wearables, a 1.5-year-old, Vancouver, B.C.-based company that creates custom, 3D printed gear, has raised $3.5 million in seed funding led byEclipse VC (formerly Formation 8 Hardware Fund), with participation from Real Ventures, Asimov Ventures, Evonik Industries, and MAS Holdings

PE Deals (2 deals)

iKang Healthcare Group (Nasdaq: KANG), a Chinese provider of medical examinations and healthcare services, has received a non-binding takeover proposal that would value the company at around $1.48 billion, or $44 per share. That’s a 36.9% premium to where the company’s shares were trading in August, before receiving a $35.60 per share buyout bid from company chairman and CEO Ligang Zhang (working with FountainVest Partners). Those involved in the new takeover bid include Meinian Onehealth Healthcare, Shenzhen Ping An Decheng Investment Co., Taiping Guofa Capital Management Co., Huatai Ruilian, Sequoia China Investment Management and Cathay Capital Private Equity

 GHO Capital has acquired Quotient Clinical, a UK-based provider of outsourced, early-stage drug development services to the pharma industry, from Bridgepoint Development Capital. No financial terms were disclosed

Other Deals (1 deals)

Sanofi (Paris: SAN) has retained Lazard to manage either sale of listing of itsMerial animal health unit, which could be valued at upwards of €12 billion

Sources: Term Sheet, Financial Times, StrictlyVC, TechinAsia, CrunchBase, TechCrunch, Bloomberg

The Propell Group

#healthtech #asia